Windtree Therapeutics, Inc. (WINT) Dividend History

Company News

• Evofem Revenue Jumps 16 Percent in Q2

  Evofem Biosciences reported Q2 2025 financial results with 16% revenue growth to $4.8 million, driven by SOLOSEC acquisition and PHEXXI price adjustment. Despite operational improvements, the company experienced a net loss of $1.8 million and faces liquidity challenges ahead of a pending merger with Aditxt.

  The Motley Fool

  Featured Companies: ADTX
• Windtree Therapeutics Announces Up To $520 Million in New Funding to Amplify BNB Cryptocurrency Treasury Strategy

  Windtree Therapeutics secures up to $520 million in funding through an equity line of credit and stock purchase agreement, with 99% of proceeds dedicated to acquiring BNB cryptocurrency as part of its innovative treasury strategy.

  GlobeNewswire Inc.
• Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics

  Evofem Biosciences has entered into an agreement with Windtree Therapeutics to reduce the manufacturing cost of its contraceptive product PHEXXI by 55-60%. This will allow Evofem to expand PHEXXI's global availability, particularly in price-sensitive markets.

  Benzinga
• Eagle Point Income reports NAV per share and quarterly earnings By Investing.com - Investing.com

  Windtree Therapeutics, a biotechnology firm, has secured $200,000 in private notes, including senior secured and unsecured promissory notes. The company has also seen recent developments such as a reverse stock split and securing new financing options.

  Investing.com
• 3 Penny Stocks To Watch Before Next Week; Time To Buy?

  3 Penny Stocks To Watch Now The post 3 Penny Stocks To Watch Before Next Week; Time To Buy? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

  PennyStocks

  Featured Companies: ABEO ARDX